drugset / Trial / NCT05377424

Adenosine 2A Receptor Antagonism and AIH in ALS

NCT05377424

Phase 1/2 Active not recruiting 40 enrolled University of Florida ALS Association · collab
RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this research study is to determine the effects of a medication, istradefylline, in conjunction with breathing air with reduced oxygen for short periods of time (called acute intermittent hypoxia, or AIH), on breathing. This project will study breathing in people with amyotrophic lateral sclerosis (ALS) and unaffected, age-matched adults. Istradefylline is prescribed to increase movement in people with other neuromuscular conditions. A recently completed study found that people with ALS took deeper breaths, 60 minutes after using AIH.

Timeline

Start
2022-06-21
Primary completion
2026-01-26
Completion
2026-08-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Istradefylline Small molecule 20 mg Oral